Drug intelligence / Profile preview

EP-0146

Development stage: Unknown
Lead developer: Chengdu Easton Biopharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

EP-0146 is a potent and highly selective small molecule inhibitor of the RET (Rearranged during Transfection) tyrosine kinase, developed by Easton Biopharmaceuticals. It is designed to target oncogenic RET alterations, including chromosomal rearrangements (fusions) and point mutations, which are key drivers in various cancers such as non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). By inhibiting RET kinase activity, EP-0146 blocks downstream signaling pathways, such as MAPK/ERK and PI3K/AKT, that promote tumor cell proliferation and survival. The drug is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors harboring RET gene alterations.

Targets

RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on EP-0146.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP-0146.

Explore the full profile